Rapport Therapeutics
RAPP
55 hedge funds and large institutions have $582M invested in Rapport Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 10 closing their positions.
228% more capital inflows, than outflows
Capital inflows: $87.4M | Capital outflows: $26.6M
200% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 10
57% more funds holding
Funds holding: 35 → 55 (+20)
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
3.29% more ownership
Funds ownership: 74.47% → 77.76% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$26.8M |
| 2 |
BlackRock
New York
|
+$12.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.39M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$8.14M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.73M |
| 3 |
Millennium Management
New York
|
-$2.72M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.26M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$1.63M |
RAPP Hedge Fund Activity: Q3 2024 in Review
55 of the 6,985 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q3 2024, worth a combined $582M — down 1.9% from $593M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RAPP positions and 10 closed out — a net gain of 20 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $26.8M. The largest seller was Artal Group, exiting entirely with an estimated $8.14M sold.
- 55 institutional investors held Rapport Therapeutics (RAPP) as of Q3 2024, up from 35 in Q2 2024.
- Funds reported $582M of Rapport Therapeutics stock for Q3 2024, down 1.9% quarter-over-quarter.
- 30 funds opened new Rapport Therapeutics positions in Q3 2024 and 10 closed out, a net change of +20 holders.
- The largest Rapport Therapeutics buyer in Q3 2024 was Goldman Sachs, an estimated $26.8M added.
- The largest Rapport Therapeutics seller in Q3 2024 was Artal Group, an estimated $8.14M sold.
Based on aggregated 13F filings for Q3 2024.